Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07046611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children

Study acronym: KLaSSEC
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 3, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2025 to Jul 2, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sohag University
498 trials monitored
See 2 trials at risk
Epilepsy
769 trials monitored
See 48 trials at risk
About 40% of children with generalized convulsive status epilepticus (GCSE) are not terminated by first-line benzodiazepines (BDZs), and approximately 50% of BDZ-refractory GCSE are not controlled by second-line antiseizure medications. This study investigates the efficacy of ketamine-levetiracetam combination vs. levetiracetam alone for treating children with BDZ-refractory GCSE.
Trial Details
NCT Number NCT07046611
Lead Sponsor Sohag University
Conditions
(from sponsor)		 Generalized Convulsive Status Epilepticus
Related terms Status Epilepticus
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov